{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:33:22Z","timestamp":1761741202598,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":247,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clinsp.2022.100113","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:28:05Z","timestamp":1662942485000},"page":"100113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Guillain-Barre syndrome related to SARS-CoV-2 vaccinations"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-7305","authenticated-orcid":false,"given":"Josef","family":"Finsterer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0694-8674","authenticated-orcid":false,"given":"Carla A.","family":"Scorza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-4748","authenticated-orcid":false,"given":"Fulvio A.","family":"Scorza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clinsp.2022.100113_bib0001","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ana.26065","article-title":"ANA investigates: neurological complications of COVID-19 vaccines","volume":"89","author":"Goss","year":"2021","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.clinsp.2022.100113_bib0002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ane.13451","article-title":"SARS-CoV-2 vaccines are not free of neurological side effects","volume":"144","author":"Finsterer","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clinsp.2022.100113_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106887","article-title":"Guillain-Barr\u00e9 syndrome after AstraZeneca COVID-19-vaccination: a causal or casual association?","volume":"208","author":"Introna","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.clinsp.2022.100113_bib0004","doi-asserted-by":"crossref","first-page":"e3286","DOI":"10.6061\/clinics\/2021\/e3286","article-title":"Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients","volume":"76","author":"Finsterer","year":"2021","journal-title":"Clinics"},{"key":"10.1016\/j.clinsp.2022.100113_bib0005","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices \u2012 United States, July 2021","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinsp.2022.100113_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108818","article-title":"Guillain-Barr\u00e9 syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine","volume":"230","author":"Garc\u00eda-Grimshaw","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clinsp.2022.100113_bib0007","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"ENSEMBLE study group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinsp.2022.100113_bib0008","unstructured":"COVID-19 vaccine safety update of the European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf."},{"key":"10.1016\/j.clinsp.2022.100113_bib0009","article-title":"Exacerbating Guillain-Barr\u00e9 syndrome eight days after vector-based COVID-19 vaccination","volume":"2021","author":"Finsterer","year":"2021","journal-title":"Case Rep Infect Dis"},{"issue":"2","key":"10.1016\/j.clinsp.2022.100113_bib0010","first-page":"e13426","article-title":"Neurological complications of COVID-19: Guillain-Barre Syndrome following Pfizer COVID-19 vaccine","volume":"13","author":"Waheed","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.clinsp.2022.100113_bib0011","article-title":"SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome","volume":"77","author":"Finsterer","year":"2022","journal-title":"Clinics"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222033142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222033142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:56:36Z","timestamp":1761720996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222033142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":11,"alternative-id":["S1807593222033142"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2022.100113","relation":{},"ISSN":["1807-5932"],"issn-type":[{"type":"print","value":"1807-5932"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guillain-Barre syndrome related to SARS-CoV-2 vaccinations","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2022.100113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100113"}}